GamaMabs Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GamaMabs Pharma - overview
Location
Toulouse, -, France
Primary Industry
Pharmaceuticals
About
GamaMabs Pharma is based in France and focuses on the development of therapeutic antibodies to treat gynaecological cancers.
Current Investors
Andera Partners, IXO Private Equity, Bpifrance Investissement
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.gamamabs.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
GamaMabs Pharma - timeline of key events
GamaMabs Pharma - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | 20,000 | - | - | - | 5,845,667 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (3,910,449) | (4,118,953) | (7,334,826) | (8,500,616) | (6,540,548) | (3,671,433) | 1,905,295 | - | - | - |
| Operating Income (USD) | (3,940,964) | (4,166,058) | (7,450,800) | (8,832,234) | (6,884,872) | (3,807,981) | 1,798,727 | - | - | - |
| Operating Margin | - | - | (37254.0%) | - | - | - | 30.8% | - | - | - |
| % EBITDA Margin | - | - | (36674.1%) | - | - | - | 32.6% | - | - | - |
| NET Income (USD) | (3,054,548) | (3,056,948) | (5,555,943) | (6,101,826) | (5,153,254) | (2,456,757) | 2,366,866 | - | - | - |
| % Net Margin | - | - | (27779.7%) | - | - | - | 40.5% | - | - | - |
GamaMabs Pharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.